The Journal of infectious diseases · 2026
Cefazolin Inoculum Effect and Cefazolin Microbiological Treatment Failure in Serious Methicillin-Susceptible Staphylococcus aureus Infections: A Multicenter Retrospective Cohort Study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jeffs Mitchell A, Li Nicole, Ogunkoya Oluwalade, Duncan D Brody, Lo Carson K L, Hall Clayton W, Nemer Ameera, Alzarnougi Elaf, Lo Calvin Ka-Fung, Monti Emma B, Al Baluki Thuwiba, Shi Zong Heng, Li Xena X, Sheth Prameet M, Lohans Christopher T, Bai Anthony D
Аннотация
BACKGROUND: It remains unclear if cefazolin inoculum effect (CzIE) translates to poorer clinical outcomes in patients with methicillin-susceptible Staphylococcus aureus (MSSA) infections who were treated with cefazolin.
METHODS: This retrospective cohort study across 5 hospitals in Ontario, Canada, from 2021 to 2025 included adult patients who received cefazolin treatment for serious MSSA infection based on blood or deep sterile site culture growth. CzIE was defined as a ≥4-fold increase in cefazolin minimum inhibitory concentration to ≥16 μg/mL at a high inoculum based on broth microdilution assay. Patients were followed to 90 days. Primary outcome was all-cause mortality. Secondary outcome was microbiological treatment failure based on culture growth of MSSA after 1 week of cefazolin treatment. Potential confounders were adjusted using propensity score weighting, and a competing risk model for microbiological treatment failure was used to account for mortality as a competing event.
RESULTS: Of 259 patients, 92 (35.5%) patients had an MSSA isolate that displayed CzIE. The 90-day mortality rate was 19/92 (20.7%) and 37/167 (22.2%) in the CzIE-positive and -negative groups, respectively, with adjusted risk difference of 0.6% (95% CI, -9.0% to 10.2%; P = .9060). Microbiological treatment failure occurred in 19/92 (20.7%) and 10/167 (6.0%) from the CzIE-positive and -negative groups, respectively, with adjusted subdistribution hazard ratio of 3.12 (95% CI, 1.38-7.08; P = .0065) in a competing risk model.
CONCLUSIONS: CzIE was associated with a significantly increased risk of microbiological treatment failure. CzIE testing may be useful in guiding antibiotic treatment for serious MSSA infections.
METHODS: This retrospective cohort study across 5 hospitals in Ontario, Canada, from 2021 to 2025 included adult patients who received cefazolin treatment for serious MSSA infection based on blood or deep sterile site culture growth. CzIE was defined as a ≥4-fold increase in cefazolin minimum inhibitory concentration to ≥16 μg/mL at a high inoculum based on broth microdilution assay. Patients were followed to 90 days. Primary outcome was all-cause mortality. Secondary outcome was microbiological treatment failure based on culture growth of MSSA after 1 week of cefazolin treatment. Potential confounders were adjusted using propensity score weighting, and a competing risk model for microbiological treatment failure was used to account for mortality as a competing event.
RESULTS: Of 259 patients, 92 (35.5%) patients had an MSSA isolate that displayed CzIE. The 90-day mortality rate was 19/92 (20.7%) and 37/167 (22.2%) in the CzIE-positive and -negative groups, respectively, with adjusted risk difference of 0.6% (95% CI, -9.0% to 10.2%; P = .9060). Microbiological treatment failure occurred in 19/92 (20.7%) and 10/167 (6.0%) from the CzIE-positive and -negative groups, respectively, with adjusted subdistribution hazard ratio of 3.12 (95% CI, 1.38-7.08; P = .0065) in a competing risk model.
CONCLUSIONS: CzIE was associated with a significantly increased risk of microbiological treatment failure. CzIE testing may be useful in guiding antibiotic treatment for serious MSSA infections.